Evaluation of the role of UGT1A1 genotype testing in colorectal cancer patients administered irinotecan and the occurence of grade 3 and 4 neutropenia.

被引：2
|
作者：
Patel, Sushma M.
Chan, Jim
Hui, Rita L.
Spence, Michele M.
机构：
[1] Kaiser Permanente, Oakland, CA USA
[2] Kaiser Permanente, Downey, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.412
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
412
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A homozygous UGT1A1*28 genotype appears to predict grade 3−4 treatment-induced neutropenia in patients receiving irinotecan,
    Reactions Weekly, 2010, 1292 (1) : 3 - 3
  • [2] Clinical Implications of UGT1A1*28 Genotype Testing in Colorectal Cancer Patients
    Shulman, Katerina
    Cohen, Ilana
    Barnett-Griness, Ofra
    Kuten, Abraham
    Gruber, Stephen B.
    Lejbkowicz, Flavio
    Rennert, Gad
    CANCER, 2011, 117 (14) : 3156 - 3162
  • [3] Clinical implications of UGT1A1☆28 genotype testing in colorectal cancer patients
    Shulman, Katerina
    Cohen, Ilana
    Barnett-Griness, Ofra
    Gruber, Stephen B.
    Lejbkowicz, Flavio
    Rennert, Gad
    CANCER RESEARCH, 2010, 70
  • [4] Evaluation of severe neutropenia and diarrhea in Asian cancer patients receiving UGT1A1 genotype-guided irinotecan dosing.
    Sutiman, Natalia
    Ramasamy, Saminathan
    Ng, Chau Hsien Matthew
    Choo, SuPin
    Wenrui, Rachel Lim
    Ling, Clarinda Chua Wei
    Kuang, John Chia Whay
    Tan, Iain B.
    Chowbay, Balram
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
    Kweekel, D. M.
    Gelderblom, H.
    Van der Straaten, T.
    Antonini, N. F.
    Punt, C. J. A.
    Guchelaar, H-J
    BRITISH JOURNAL OF CANCER, 2008, 99 (02) : 275 - 282
  • [6] UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
    D M Kweekel
    H Gelderblom
    T Van der Straaten
    N F Antonini
    C J A Punt
    H-J Guchelaar
    British Journal of Cancer, 2008, 99 : 275 - 282
  • [7] UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters
    Hoskins, Janelle M.
    Goldberg, Richard M.
    Qu, Pingping
    Ibrahim, Joseph G.
    McLeod, Howard L.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (17) : 1290 - 1295
  • [8] Correlation of UGT1A1*28 and *6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients
    Atasilp, Chalirmporn
    Chansriwong, Pichai
    Sirachainan, Ekapob
    Reungwetwattana, Thanyanan
    Chamnanphon, Montri
    Puangpetch, Apichaya
    Wongwaisayawan, Sansanee
    Sukasem, Chonlaphat
    DRUG METABOLISM AND PHARMACOKINETICS, 2016, 31 (01) : 90 - 94
  • [9] The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
    Toffoli, Giuseppe
    Cecchin, Erika
    Corona, Giuseppe
    Russo, Antonio
    Buonadonna, Angela
    D'Andrea, Mario
    Pasetto, Lara Maria
    Pessa, Sergio
    Errante, Domenico
    De Pangher, Vincenzo
    Giusto, Mauro
    Medici, Michele
    Gaion, Fernando
    Sandri, Paolo
    Galligioni, Enzo
    Bonura, Salvatore
    Boccalon, Massimo
    Biason, Paola
    Frustaci, Sergio
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) : 3061 - 3068
  • [10] ROLE OF UGT1A1*6 IN IRINOTECAN TOXICITY IN JAPANESE CANCER PATIENTS
    Kakihata, K.
    Sai, K.
    Mori, A.
    Saito, Y.
    Suzuki, T.
    Ando, Y.
    Hasegawa, Y.
    Sawada, J.
    Yoshida, T.
    ANNALS OF ONCOLOGY, 2008, 19 : 50 - 50
12345